J. Goldman & CO LP Amicus Therapeutics, Inc. Call Options Transaction History

J. Goldman & CO LP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 14, 2023	BUY	$11.78 - $13.86 $477,090 - $561,330	40,500 New	40,500 $492,000
Q1 2023 May 15, 2023	SELL	$10.91 - $13.54 $163,650 - $203,100	-15,000 Reduced 20.0%	60,000 $665,000
Q4 2022 Feb 14, 2023	BUY	$9.89 - $12.7 $741,750 - $952,500	75,000 New	75,000 $915,000
Q4 2021 Feb 14, 2022	SELL	$9.82 - $12.44 $1.59 Million - $2.02 Million	-162,000 Reduced 96.2%	6,400 $74,000
Q3 2021 Nov 15, 2021	BUY	$8.74 - $11.84 $728,042 - $986,272	83,300 Added 97.88%	168,400 $1.61 Million
Q3 2019 Nov 14, 2019	BUY	$8.02 - $13.25 $682,502 - $1.13 Million	85,100 New	85,100 $683,000
Q2 2018 Aug 14, 2018	SELL	$13.13 - $17.09 $1.71 Million - $2.22 Million	-130,000 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$13.76 - $17.12 $1.79 Million - $2.23 Million	130,000 New	130,000 $1.96 Million

311

314M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.53B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.